Singh M, Lin J, Hocker T L, Tsao H
Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA.
Br J Dermatol. 2008 Jan;158(1):15-21. doi: 10.1111/j.1365-2133.2007.08316.x. Epub 2007 Nov 28.
Melanoma therapy is moving away from combinatorial approaches and towards newer targeted strategies. With the identification of mutations in various RAS pathway genes, there are now tremendous opportunities to bring inhibitors of RAS signalling to the clinical arena.
黑色素瘤治疗正从联合治疗方法转向更新的靶向治疗策略。随着各种RAS通路基因中突变的发现,现在有巨大的机会将RAS信号抑制剂引入临床领域。